JP2022548957A5 - - Google Patents
Info
- Publication number
- JP2022548957A5 JP2022548957A5 JP2022517933A JP2022517933A JP2022548957A5 JP 2022548957 A5 JP2022548957 A5 JP 2022548957A5 JP 2022517933 A JP2022517933 A JP 2022517933A JP 2022517933 A JP2022517933 A JP 2022517933A JP 2022548957 A5 JP2022548957 A5 JP 2022548957A5
- Authority
- JP
- Japan
- Prior art keywords
- mrna
- nucleic acid
- isolated nucleic
- rnase
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962902604P | 2019-09-19 | 2019-09-19 | |
| US62/902,604 | 2019-09-19 | ||
| PCT/US2020/051583 WO2021055811A1 (en) | 2019-09-19 | 2020-09-18 | Cap guides and methods of use thereof for rna mapping |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022548957A JP2022548957A (ja) | 2022-11-22 |
| JP2022548957A5 true JP2022548957A5 (enExample) | 2023-09-28 |
Family
ID=74884727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022517933A Pending JP2022548957A (ja) | 2019-09-19 | 2020-09-18 | キャップガイド及びｒｎａマッピングのためのその使用方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20220349006A1 (enExample) |
| EP (1) | EP4031666A4 (enExample) |
| JP (1) | JP2022548957A (enExample) |
| AU (1) | AU2020348860A1 (enExample) |
| CA (1) | CA3155014A1 (enExample) |
| WO (1) | WO2021055811A1 (enExample) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| US11364292B2 (en) | 2015-07-21 | 2022-06-21 | Modernatx, Inc. | CHIKV RNA vaccines |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2017070601A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Nucleic acid vaccines for varicella zoster virus (vzv) |
| AU2016342045A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| WO2017070624A1 (en) | 2015-10-22 | 2017-04-27 | Modernatx, Inc. | Tropical disease vaccines |
| PL3386484T3 (pl) | 2015-12-10 | 2022-07-25 | Modernatx, Inc. | Kompozycje i sposoby dostarczania środków terapeutycznych |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| EP3528821A4 (en) | 2016-10-21 | 2020-07-01 | ModernaTX, Inc. | HUMAN CYTOMEGALOVIRUS VACCINE |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| US11384352B2 (en) | 2016-12-13 | 2022-07-12 | Modernatx, Inc. | RNA affinity purification |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170270A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Varicella zoster virus (vzv) vaccine |
| EP3595713A4 (en) | 2017-03-15 | 2021-01-13 | ModernaTX, Inc. | RESPIRATORY SYNCYTIAL VIRUS Vaccine |
| EP3595676A4 (en) | 2017-03-17 | 2021-05-05 | Modernatx, Inc. | RNA VACCINES AGAINST ZOONOSES |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| EP3668979A4 (en) | 2017-08-18 | 2021-06-02 | Modernatx, Inc. | METHOD OF HPLC ANALYSIS |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| WO2019055807A1 (en) | 2017-09-14 | 2019-03-21 | Modernatx, Inc. | RNA VACCINES AGAINST ZIKA VIRUS |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| US11851694B1 (en) | 2019-02-20 | 2023-12-26 | Modernatx, Inc. | High fidelity in vitro transcription |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| IL297419B2 (en) | 2020-04-22 | 2025-02-01 | BioNTech SE | Coronavirus vaccine |
| US11406703B2 (en) | 2020-08-25 | 2022-08-09 | Modernatx, Inc. | Human cytomegalovirus vaccine |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| JP2024512780A (ja) * | 2021-04-01 | 2024-03-19 | モデルナティエックス インコーポレイテッド | 多価ｒｎａ組成物中のｒｎａ種の識別及び比率決定のための方法 |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| AU2024304484A1 (en) * | 2023-06-14 | 2026-02-05 | Sanofi Pasteur Inc. | Methods of simultaneously identifying or quantifying capping and tailing modifications of messenger rna |
| US12553042B2 (en) * | 2023-12-01 | 2026-02-17 | Recode Therapeutics, Inc. | Method for quantifying an amount of capped messenger RNA |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6346614B1 (en) * | 1992-07-23 | 2002-02-12 | Hybridon, Inc. | Hybrid oligonucleotide phosphorothioates |
| US5605798A (en) | 1993-01-07 | 1997-02-25 | Sequenom, Inc. | DNA diagnostic based on mass spectrometry |
| US5684143A (en) | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
| US9254311B2 (en) * | 2012-04-02 | 2016-02-09 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of proteins |
| WO2014144039A1 (en) * | 2013-03-15 | 2014-09-18 | Moderna Therapeutics, Inc. | Characterization of mrna molecules |
| CA2969619A1 (en) * | 2014-12-03 | 2016-06-09 | Agilent Technologies, Inc. | Guide rna with chemical modifications |
| ES2763822T3 (es) * | 2015-12-09 | 2020-06-01 | Novartis Ag | Análisis exento de marcas de la eficacia de la adición de caperuzas al arn utilizando rnasa h, sondas y cromatografía líquida/espectrometría de masas |
| WO2018081462A1 (en) * | 2016-10-26 | 2018-05-03 | Modernatx, Inc. | Methods and compositions for rna mapping |
| WO2019051428A1 (en) * | 2017-09-11 | 2019-03-14 | The Regents Of The University Of California | CAS9 ANTIBODY MEDIA ADMINISTRATION TO MAMMALIAN CELLS |
-
2020
- 2020-09-18 WO PCT/US2020/051583 patent/WO2021055811A1/en not_active Ceased
- 2020-09-18 EP EP20864436.9A patent/EP4031666A4/en active Pending
- 2020-09-18 US US17/761,420 patent/US20220349006A1/en active Pending
- 2020-09-18 CA CA3155014A patent/CA3155014A1/en active Pending
- 2020-09-18 JP JP2022517933A patent/JP2022548957A/ja active Pending
- 2020-09-18 AU AU2020348860A patent/AU2020348860A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022548957A5 (enExample) | ||
| AU2021266291B2 (en) | Allele-specific amplification using a composition of overlapping non-allele-specific primer and allele-specific blocker oligonucleotides | |
| JP2005503802A5 (enExample) | ||
| JP2012531202A5 (enExample) | ||
| KR890701764A (ko) | 표적 뉴클레오티드 서열의 선택적 증식 | |
| BR0214741A (pt) | Iniciador de controle de anelamento para melhorar a especificidade de anelamento na amplificação de ácido nucléico, kit, métodos para amplificar uma sequência de ácido nucléico de um dna ou uma mistura de ácidos nucléicos, e para amplificar seletivamente uma sequência de ácido nucléico alvo de um dna ou uma mistura de ácidos nucléicos, e uma sequência de ácido nucléico alvo a partir de um mrna, método para detectar a complementaridade de dna ao mrna diferencialmente expresso em duas ou mais amostras de ácido nucléico, métodos para amplificar rapidamente um fragmento de cdna e dna alvo, e para amplificar uma população de cdnas de filamento duplo de comprimento completo complementar aos mrnas, e cdnas de filamento duplo enriquecidos em 5' complementares aos mrnas, método para amplificar mais do que uma sequência de nucleotìdeo alvo simultaneamente, métodos para produzir uma impressão digital de dna de gdna, e de rna de uma amostra de mrna, método para identificar segmentos de homologia conservada em uma famìlia de multigene a partir de uma amostra de mrna, método para a mutagênese em um ácido nucléico alvo, e, uso do iniciador | |
| JP2009035530A5 (enExample) | ||
| WO2010090857A3 (en) | Methods for amplifying hepatitis c virus nucleic acids | |
| AU2011230496A8 (en) | Methods for enhancing nucleic acid hybridization | |
| JP2012514461A (ja) | 標的核酸の交差プライミング増幅 | |
| JP2011501663A5 (enExample) | ||
| JP4931595B2 (ja) | Ｒｎａ配列の増幅のための方法 | |
| JP6006814B2 (ja) | 核酸増幅用プライマーの設計方法、核酸増幅用プライマーの製造方法、核酸増幅用プライマー、プライマーセット、および核酸の増幅方法 | |
| WO2017138484A1 (ja) | 標的核酸を検出する方法およびそれに用いる核酸プローブ | |
| JP2014527823A5 (enExample) | ||
| JP2006521824A5 (enExample) | ||
| JPWO2009119331A1 (ja) | サイトケラチン７のｍＲＮＡの検出用プライマを含む試薬 | |
| CN110651050A (zh) | 用于检测低频突变的靶向富集方法和试剂盒 | |
| EP3286331A1 (en) | Method for hybridizing a nucleic acid molecule | |
| JP2018500936A5 (enExample) | ||
| JPWO2023013613A5 (enExample) | ||
| JP7306722B2 (ja) | プライマー及びその使用 | |
| JP2006345800A5 (enExample) | ||
| JP2007267636A (ja) | 核酸製造法および核酸増幅用プライマーセット | |
| WO2024238385A3 (en) | Single-stranded loop oligonucleotides |